Wang KL, Xing HQ, Zhao H, Liu JW, Gao DL, Zhang XH, Yao HY, Yan L, Zhao J. Efficacy and tolerability of low-dose interferon-α in hemodialysis patients with chronic hepatitis C virus infection. World J Gastroenterol 2014; 20(14): 4071-4075 [PMID: 24744598 DOI: 10.3748/wjg.v20.i14.4071]
Corresponding Author of This Article
Jun Zhao, Professor, Department of Blood Purification, 302 Hospital of the People’s Liberation Army, Xisihuan Zhonglu No. 100, Fengtai District, Beijing 100039, China. zhj68@263.net
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Research Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Wang KL, Xing HQ, Zhao H, Liu JW, Gao DL, Zhang XH, Yao HY, Yan L, Zhao J. Efficacy and tolerability of low-dose interferon-α in hemodialysis patients with chronic hepatitis C virus infection. World J Gastroenterol 2014; 20(14): 4071-4075 [PMID: 24744598 DOI: 10.3748/wjg.v20.i14.4071]
World J Gastroenterol. Apr 14, 2014; 20(14): 4071-4075 Published online Apr 14, 2014. doi: 10.3748/wjg.v20.i14.4071
Efficacy and tolerability of low-dose interferon-α in hemodialysis patients with chronic hepatitis C virus infection
Kai-Li Wang, Han-Qian Xing, Hong Zhao, Jun-Wei Liu, Deng-Lian Gao, Jun Zhao, Li Yan, Hong-Yu Yao, Xue-Hua Zhang
Kai-Li Wang, Han-Qian Xing, Hong Zhao, Jun-Wei Liu, Deng-Lian Gao, Xue-Hua Zhang, Hong-Yu Yao, Li Yan, Jun Zhao, Department of Blood Purification, 302 Hospital of the People’s Liberation Army, Beijing 100039, China
Author contributions: Wang KL and Xing HQ contributed equally to the treatment of patients, analyzing of data, and writing of the manuscript; Zhao H participated in the treatment of patients and collecting of data; Liu JW, Gao DL, Zhang XH, Yao HY, and Yan L participated in data collection and patient follow-up; Zhao J designed the manuscript and edited the final draft.
Correspondence to: Jun Zhao, Professor, Department of Blood Purification, 302 Hospital of the People’s Liberation Army, Xisihuan Zhonglu No. 100, Fengtai District, Beijing 100039, China. zhj68@263.net
Telephone: +86-10-66933438 Fax: +86-10-66933434
Received: September 10, 2013 Revised: November 21, 2013 Accepted: January 3, 2014 Published online: April 14, 2014 Processing time: 215 Days and 21.1 Hours
Core Tip
Core tip: The most appropriate treatment for hepatitis C virus (HCV)-positive hemodialysis patients is unknown, and the available treatments have only been assessed in a limited manner. Therefore, this study evaluated the efficacy and tolerability of treatment with low-dose standard or pegylated interferon (PEG-IFN) in HCV-positive hemodialysis patients. The results of the study indicated that low-dose interferon monotherapy, either PEG-IFNα-2a or standard interferon α-2b, is an effective treatment option for HCV-positive hemodialysis patients. Anemia was the most frequently encountered adverse event, but this could be managed with erythropoietin. These results provide important information for clinicians faced with these treatment decisions.
